Merck KGaA (XTRA:MRK) recently raised its 2026 guidance, now expecting group net sales of about €21b to €21.8b and EPS pre of €7.90 to €8.60, which has refocused attention on the stock.
See our latest analysis for Merck KGaA.
At a share price of €138.35, Merck KGaA has seen a 9.45% 90 day share price return and a 14.06% year to date share price return. The 1 year total shareholder return of 26.40% contrasts with declines over 3 and 5 years, pointing to renewed but still fragile momentum after the upgraded 2026 guidance and recent M Ventures funding activity.
If you are reassessing healthcare exposure after Merck KGaA’s guidance shift, it can be useful to see what else is moving in the sector via the 133 healthcare AI stocks
After a sharp reset in expectations and with a higher 2026 target now on the table, Merck KGaA is now focused on a different question: Does the current valuation still leave enough upside for new buyers relative to the risks?
Most Popular Narrative: 5.4% Undervalued
At €138.35, the most followed narrative for Merck KGaA points to a fair value of about €146.29, which implies a modest upside based on its cash flow and earnings profile discounted at 5.26%.
The robust and accelerating growth in the Life Science segment, particularly Process Solutions (with double-digit organic growth, strong order intake, and a sustained book-to-bill above 1), is being driven by increasing global investment and demand in biotechnology and advanced biologics manufacturing, this supports top-line revenue growth and higher operating leverage.
Curious what sits behind that confidence in Life Science and Healthcare, and how margins, growth and the chosen profit multiple all fit together? The narrative walks through a detailed revenue build, expected profitability shift and the valuation multiple it thinks the market can support over time.
Result: Fair Value of €146.29 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside case for Merck KGaA still hinges on the successful integration of deals such as SpringWorks and Bio-Techne, as well as on managing Electronics headwinds and upcoming patent expiries.
Find out about the key risks to this Merck KGaA narrative.
Next Steps
Given the mix of optimism and caution around Merck KGaA, it makes sense to review the data yourself and decide quickly where you stand. To see what is driving that optimism, take a closer look at the 3 key rewards
Looking for more investment ideas beyond Merck KGaA?
Before you move on, take a moment to widen your watchlist. Fresh ideas now can make a real difference to how your portfolio looks a few years from today.
- Target resilient cash generators by scanning companies with dependable balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (433 results).
- Hunt for potential bargains using the screener containing 608 high quality undiscovered gems that may not yet be crowded with attention but already show strong financial quality.
- Strengthen your income stream by reviewing companies in the 432 dividend fortresses that combine higher yields with a focus on stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com